查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715772

病毒載體製造市場（按載體類型、工作流程、交付方式、技術、適應症、應用和最終用戶）—2025-2030 年全球預測

Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年病毒載體製造市場價值為 91.9 億美元，預計 2025 年將成長至 110 億美元，複合年成長率為 20.03%，預計到 2030 年將達到 275 億美元。

介紹

主要市場統計數據
基準年2024年 91.9億美元
預計年份：2025年 110億美元
預測年份 2030 275億美元
複合年成長率（%） 20.03%

近年來，病毒載體製造的動態部分已成為先進治療方法和突破性生物醫學研究的關鍵。創新技術、嚴謹的科學研究和不斷發展的法律規範的結合正在加速病毒載體在不同治療領域的開發和應用。這項變革格局的特點是強勁成長，這得益於對個人化醫療、基因療法和疫苗的需求不斷成長。手術精度的流程最佳化和嚴格的品管措施確保這些載體符合最高的安全性和有效性標準。

我們將標靶治療從實驗室帶到臨床的能力依賴於不斷改進的複雜製造流程。上游和下游製程的進步使製造商能夠在不損害產品完整性的情況下實現可擴展性和業務效率。因此，隨著生物治療產業朝著更易於獲取和更有效的未來邁進，大量市場研究強調了利用尖端製造技術和法規遵循的重要性。

病毒載體製造的歷程不僅是技術進步的歷程，也是策略市場定位的歷程。隨著投資者興趣的不斷成長以及數位技術在品質保證中的整合，該生態系統已準備好在多個疾病領域持續創新和更廣泛地應用。本介紹性概述將深入探討定義這一快速發展的製造業格局的多方面細分市場、新興趨勢以及關鍵區域和企業舉措。

改變病毒載體製造市場

病毒載體製造的當前環境正在經歷一場變革性轉變，這種轉變正在重塑老牌產業參與企業和新興企業應對製造挑戰和市場機會的方式。快速的技術進步和下一代生物加工技術的整合徹底改變了載體的設計、最佳化和部署方式。產業領導者透過採用模組化製造策略和利用流程自動化不斷適應這些變化。

自動化和即時分析的重大發展正在開啟業務效率的新時代。這種不斷發展的情況更加重視跨多個生產階段的流程整合，從而整合先前孤立的工作流程。同時，不斷發展的監管和品質保證框架繼續推動製造商採用嚴格的驗證方法，即使是最複雜的產品也可以在不影響品質或安全的情況下快速擴大規模。

除了技術範式之外，一個值得注意的趨勢是經營模式的多樣化。許多公司正在從傳統的線性生產路徑轉向更靈活、可自訂的平台，以靈活回應市場需求。對先進精製技術和新型轉染方法等新子領域的策略性投資不僅重新定義了產品生命週期，也為臨床成功和商業性可行性設定了新的基準。這段前所未有的變革時期凸顯了持續進行策略重新評估和創新的必要性，這不僅可以促進卓越營運，還可以提供抓住全球市場機會的競爭優勢。

此外，產業趨勢反映出人們越來越意識到生技藥品生產基地所面臨的業務挑戰和巨大機會。如今，重點是將數位解決方案與傳統製造技術相結合，創建能夠抵禦市場波動並適應不斷變化的研究需求的混合模式。總的來說，這些變革性的變化為未來鋪平了道路，病毒載體製造不僅能滿足日益成長的全球健康需求，而且還能透過效率、永續性和精確性的視角來實現。

關鍵細分洞察

病毒載體製造市場區隔複雜，相關人員可以識別具有重大創新和機會的細分市場。仔細觀察按載體類型分類的情況，可以發現多種方法，包括腺病毒載體、桿狀病毒載體、單純皰疹病毒載體、慢病毒載體、質體DNA 和逆轉錄病毒的研究。這些特定類別突顯了標靶治療中採用的多種遺傳元素和傳遞機制，對於根據臨床需求客製化生產策略至關重要。

除了向量類型之外，市場細分還將透過工作流程來呈現，其特點是下游流程和上游流程之間的分叉。下游加工分為配方和精製，每個步驟對於維持產品穩定性和法規遵循至關重要。同時，上游製程進一步透過使用反應器、細胞培養系統和客製化培養基配方進行分類，從而實現載體生產的放大和最佳化的高級客製化。

此外，透過遞送方法進行細分的細緻方法凸顯了體外和體內應用的雙重策略。在體外空間，重點是細胞再輸注和細胞遞送技術，以最佳化治療載體與人體外部標靶細胞的整合。相反，直接注射、靜脈注射和口服給藥等體內方法對於確保有效的載體遞送和體內基因改造表達至關重要。每條途徑都有獨特的挑戰和優勢，需要操作和臨床的考量。

按技術進行細分可以進一步提高市場分析的細微度。這些包括精製技術和轉染方法，前者又細分為層析法和超過濾。後者分為以化學為基礎的方法和電穿孔，在考慮產品產量和純度時，每種方法都有不同的操作優勢和技術挑戰。如此詳細的細分凸顯了能夠適應臨床和工業應用不斷變化的需求的客製化製造流程的重要性。

此外，按適應症進行市場細分可以帶來解決多樣化治療環境的見解。每種疾病，包括心血管疾病、遺傳疾病、感染疾病和代謝疾病，都需要專門的載體設計和生產方法。此外，基於應用的細分透過關注基因治療、癌症研究和疫苗治療提供了市場動態的詳細視圖。在基因治療中，進一步分為遺傳疾病、腫瘤疾病和單基因突變，揭示了個人化醫療的針對性方法。類似地，腫瘤學研究領域透過基因惰性、溶瘤病毒療法和腫瘤抑制基因等細分來描述，而疫苗學則透過癌症疫苗、感染疾病和通用感染疾病領域來繪製。

最後，根據最終用戶概況進行的市場細分為了解行業的多樣化需求提供了關鍵見解。分析涵蓋生物技術公司、製藥公司和研究機構。生技領域分為大型公司和新興企業，而製藥公司則專注於兩個領域：製造和研發。同樣，研究機構也分為學術實驗室和政府實驗室。這種分解不僅使相關人員能夠有效地分配資源和最佳化生產方法，而且還推動了與臨床和商業需求緊密結合的有針對性的創新。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 病毒載體在感染疾病疫苗生產的應用日益增多
      • 專注於個人化醫療和基因治療
      • 政府支持加強全球病毒載體生產能力
    • 限制因素
      • 生產成本高，原料不均勻
    • 機會
      • 增強視網膜結構和功能疾病的基因治療解決方案
      • 投資可擴展的製造程序，實現病毒載體的大規模生產
    • 任務
      • 複雜的法規環境確保遵守世界各地的各種標準
  • 市場區隔分析
    • 載體類型：腺病毒載體由於其強大的免疫抗原性原性和感染非分裂細胞的能力，擴大用於疫苗和基因治療
    • 應用：基因治療在治療遺傳疾病和腫瘤疾病的需求增加
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

6. 病毒載體製造市場（依載體類型）

  • 介紹
  • 腺病毒載體
  • 桿狀病毒載體
  • 單純皰疹病毒載體
  • 慢病毒載體
  • 質體DNA
  • 逆轉錄病毒

7. 病毒載體製造市場（依工作流程）

  • 介紹
  • 下游加工
    • 配方
    • 精製
  • 上游處理
    • 反應器
    • 細胞培養系統
    • 培養基配方

8. 病毒載體製造市場（以交付方式）

  • 介紹
  • Ex Vivo
    • 細胞再注射
    • 細胞轉導
  • In vivo
    • 缸內直噴
    • 靜脈注射
    • 口服途徑

9. 病毒載體製造市場（依技術）

  • 介紹
  • 淨化技術
    • 層析法
    • 超過濾
  • 轉染方法
    • 基於化學
    • 電穿孔

第 10 章病毒載體製造市場（按適應症）

  • 介紹
  • 心血管疾病
  • 遺傳性疾病
  • 感染疾病
  • 代謝紊亂

第 11 章病毒載體製造市場（按應用）

  • 介紹
  • 基因治療
    • 遺傳性疾病
    • 腫瘤疾病
    • 單基因突變
  • 腫瘤監測
    • 基因惰性
    • 溶瘤病毒療法
    • 腫瘤抑制基因
  • 疫苗
    • 癌症疫苗
    • 感染疾病
    • 通用感染疾病

第 12 章病毒載體製造市場（依最終用戶）

  • 介紹
  • 生技公司
    • 大型企業
    • Start-Ups
  • 製藥公司
    • 製造業
    • 研究與開發
  • 研究所
    • 學術實驗室
    • 政府實驗室

13.美洲病毒載體製造市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

14. 亞太病毒載體製造市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

15. 歐洲、中東和非洲病毒載體製造市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • ABL Inc.
  • Batavia Biosciences BV by CJ Cheiljedang
  • Biovian Oy
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Danaher Corporation
  • FinVector Oy
  • FUJIFILM Diosynth BIoTechnologies USA, Inc.
  • GE HealthCare Technologies, Inc.
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec SA
  • Lonza Group Ltd.
  • MaxCyte, Inc.
  • Merck KGaA
  • Miltenyi BIoTec GmbH
  • Novartis AG
  • Oxford Biomedica PLC
  • Sanofi SA
  • Sirion-BIoTech GmbH
  • Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure NV
  • VGXI, Inc. by GeneOne Life Science
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-FD3F12D54086

The Viral Vector Manufacturing Market was valued at USD 9.19 billion in 2024 and is projected to grow to USD 11.00 billion in 2025, with a CAGR of 20.03%, reaching USD 27.50 billion by 2030.

Introduction

KEY MARKET STATISTICS
Base Year [2024] USD 9.19 billion
Estimated Year [2025] USD 11.00 billion
Forecast Year [2030] USD 27.50 billion
CAGR (%) 20.03%

In recent years, the dynamic field of viral vector manufacturing has emerged as a cornerstone of advanced therapeutics and breakthrough biomedical research. The convergence of innovative technology, rigorous scientific inquiry, and evolving regulatory frameworks has accelerated the development and application of viral vectors in diverse therapeutic areas. This transformative landscape is characterized by robust growth fueled by an increasing demand for personalized medicine, gene therapies, and vaccines. Surgical precision in process optimization and stringent quality control measures ensure that these vectors meet the highest standards of safety and efficacy.

From research laboratories to clinical settings, the ability to deliver targeted treatments depends on sophisticated manufacturing processes that are continuously refined. Advances in both upstream and downstream processing have enabled manufacturers to achieve scalability and operational efficiency without compromising product integrity. Consequently, a substantial body of market research now underscores the importance of leveraging state-of-the-art production techniques and regulatory compliance as the industry marches toward a future where biotherapeutics become even more accessible and effective.

The journey of viral vector manufacturing is not only one of technological sophistication but also of strategic market positioning. With heightened investor interest and the integration of digital technologies in quality assurance, the ecosystem is primed for sustained innovation and broader applications in various disease domains. This introductory overview sets the stage for an in-depth exploration into the multifaceted segments, emerging trends, and key regional and corporate initiatives that define the manufacturing landscape in this rapidly evolving field.

Transformative Shifts in the Landscape

The current environment in viral vector manufacturing is witnessing transformative shifts that are reshaping how both established industry players and emerging companies approach production challenges and market opportunities. Rapid technological advancements and the integration of next-generation bioprocessing techniques have revolutionized the way vectors are engineered, optimized, and deployed. Industrial leaders have continually adapted to these changes by adopting modular production strategies and leveraging process automation, which together streamline scalability while meeting exacting regulatory benchmarks.

Significant developments in automation and real-time analytics have ushered in a new era of operational efficiency. This evolving landscape now places greater emphasis on process integration across multiple stages of production, leading to the consolidation of formerly siloed workflows. In parallel, evolving regulatory and quality assurance frameworks continue to push manufacturers toward rigorous validation methods, ensuring that even the most complex products can be rapidly scaled without compromising on quality or safety.

Beyond the technological paradigms, a noticeable trend is the diversification of business models. Many companies are shifting from traditional, linear production pathways to more agile and customizable platforms that can respond flexibly to market demands. Strategic investments in emerging subfields - such as advanced purification techniques and novel transfection methodologies - are not only redefining product lifecycles but are also setting new benchmarks for clinical success and commercial viability. This period of unprecedented change highlights the need for continuous strategic reassessment and innovation, which not only fosters operational excellence but also offers a competitive edge in capturing global market opportunities.

Moreover, industry trends reflect an increasing acknowledgement of both the operational challenges and the tremendous opportunities presented by the biologics manufacturing landscape. The emphasis is now firmly on integrating digital solutions with traditional production techniques, thereby creating a hybrid model that is resilient to market fluctuations and adaptable to evolving research requirements. In sum, these transformative shifts are paving the way for a future where viral vector manufacturing not only meets the growing global health demands but does so through a lens of efficiency, sustainability, and precision.

Key Segmentation Insights

The market for viral vector manufacturing is intricately segmented, allowing stakeholders to pinpoint areas of significant innovation and opportunity. A detailed examination of segmentation based on vector type reveals a broad array of approaches, including the study of adenoviral vectors, baculoviral vectors, herpes simplex vectors, lentiviral vectors, plasmid DNA, and retrovirus. These specific categories underscore the varied genetic elements and delivery mechanisms employed in targeted therapies and are critical for tailoring production strategies to clinical needs.

Moving beyond vector type, the market introduces segmentation based on workflow processes which feature a dichotomy of downstream and upstream processing. Downstream processing is methodically divided into formulation and purification, each critical for maintaining product stability and regulatory compliance. On the other hand, upstream processing is further categorized by the use of bioreactors, cell culture systems, and tailored media formulations, enabling a high degree of customization in the scaling and optimization of vector production.

Furthermore, a nuanced approach to segmentation based on the delivery method highlights the dual strategies of ex vivo and in vivo applications. In the ex vivo domain, the focus on cell re-infusion and cell transduction techniques optimizes the integration of therapeutic vectors within target cells outside of the human body. Conversely, in vivo methodologies, which include direct injection, the intravenous route, and oral administration, are pivotal in ensuring efficient vector delivery and transgene expression in living organisms. Each route presents unique challenges and advantages that require specific operational and clinical considerations.

The segmentation based on technology further adds layers of sophistication to the market analysis. It encompasses purification techniques and transfection methods, with the former subdivided into chromatography and ultrafiltration. The latter is dissected into chemical-based approaches and electroporation, each offering distinct operational benefits and technical challenges when considering product yield and purity. Such detailed segmentation highlights the importance of tailored manufacturing processes that can adapt to the evolving demands of clinical and industrial applications.

Additionally, market segmentation by disease indication provides insights into the diverse therapeutic landscapes being addressed. The focus spans across cardiovascular diseases, genetic disorders, infectious diseases, and metabolic disorders, with each indication necessitating a specialized approach in vector design and production. Moreover, the application-based segmentation offers a granular view of the market dynamics by focusing on gene therapy, oncology research, and vaccinology. In gene therapy, further classification into inherited disorders, oncological disorders, and single gene mutations reveals targeted approaches to personalized medicine. Similarly, the domain of oncology research is explicated through subdivisions like gene inactivation, oncolytic virotherapy, and tumor suppressor genes, while vaccinology is mapped through the realms of cancer vaccines, infectious diseases, and zoonotic diseases.

Lastly, market segmentation based on end user profiles provides crucial insights regarding the diverse demand in the industry. The analysis spans biotechnology companies and pharmaceutical companies, along with research institutions. The biotechnology segment itself is further divided into large enterprises and start-ups, while pharmaceutical companies focus on the dual realms of manufacturing and research and development. Equally, the research institutions are bifurcated into academic laboratories and government labs. This level of segmentation not only allows stakeholders to effectively allocate resources and optimize production methodologies but also drives targeted innovation that is closely aligned with both clinical and commercial imperatives.

Based on Vector Type, market is studied across Adenoviral Vectors, Baculoviral Vectors, Herpes Simplex Vectors, Lentiviral Vectors, Plasmid DNA, and Retrovirus.

Based on Workflow, market is studied across Downstream Processing and Upstream Processing. The Downstream Processing is further studied across Formulation and Purification. The Upstream Processing is further studied across Bioreactors, Cell Culture Systems, and Media Formulations.

Based on Delivery Method, market is studied across Ex Vivo and In Vivo. The Ex Vivo is further studied across Cell Re-infusion and Cell Transduction. The In Vivo is further studied across Direct Injection, Intravenous Route, and Oral Administration.

Based on Technology, market is studied across Purification Techniques and Transfection Methods. The Purification Techniques is further studied across Chromatography and Ultrafiltration. The Transfection Methods is further studied across Chemical-Based and Electroporation.

Based on Disease Indication, market is studied across Cardiovascular Diseases, Genetic Disorders, Infectious Diseases, and Metabolic Disorders.

Based on Application, market is studied across Gene Therapy, Oncology Research, and Vaccinology. The Gene Therapy is further studied across Inherited Disorders, Oncological Disorders, and Single Gene Mutations. The Oncology Research is further studied across Gene Inactivation, Oncolytic Virotherapy, and Tumor Suppressor Genes. The Vaccinology is further studied across Cancer Vaccines, Infectious Diseases, and Zoonotic Diseases.

Based on End User, market is studied across Biotechnology Companies, Pharmaceutical Companies, and Research Institutions. The Biotechnology Companies is further studied across Large Enterprises and Start-Ups. The Pharmaceutical Companies is further studied across Manufacturing and Research and Development. The Research Institutions is further studied across Academic Laboratories and Government Labs.

Key Regional Insights

Regional analysis reveals that the Americas continue to be a significant market driver in viral vector manufacturing, leveraging strong research ecosystems, advanced infrastructure, and high consumer demand for innovative therapies. These regions are characterized by robust investment in state-of-the-art biomanufacturing facilities that support both early-stage development and full-scale production, ensuring that the therapeutic products meet stringent quality standards and regulatory benchmarks.

In Europe, the Middle East & Africa, the market is shaped by a confluence of regulatory modernization, academic excellence, and strategic partnerships across borders. This multi-regional landscape benefits from a well-established network of research institutions and clinical centers that collaboratively drive advancements in viral vector technologies. Emphasis on precision medicine and personalized treatment modalities in these regions is driving transformative investments, particularly in emerging gene therapies and innovative vaccine developments.

The Asia-Pacific region, meanwhile, is emerging as a critical hub for both research and manufacturing excellence. Rapid industrial growth, coupled with an expanding base of skilled professionals and strong governmental support, is propelling the expansion of manufacturing capacities. The region's market dynamics are notably influenced by the accelerated adoption of advanced technologies, increased investment in research and development, and strategic initiatives aimed at capturing both domestic and international market shares. Integration of cutting-edge analytics and digital solutions further reinforces the potential for scalable, cost-effective production techniques that resonate with global demands.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

A comprehensive analysis of the market underscores the influence of several key players that have been instrumental in shaping the viral vector manufacturing landscape. Industry frontrunners such as ABL Inc. and Batavia Biosciences B.V. by CJ Cheiljedang are recognized for their innovative approaches and robust R&D frameworks. Companies like Biovian Oy and Charles River Laboratories International, Inc. have set exemplary standards in quality control and regulatory compliance, powering the development of next-generation therapeutics. Creative Biogene and Danaher Corporation also hold pivotal roles in advancing operational efficiencies through advanced process optimization techniques.

Additional noteworthy contributors such as FinVector Oy and FUJIFILM Diosynth Biotechnologies U.S.A., Inc. continually demonstrate strategic prowess through their investments in both cutting-edge technology and process automation. GE HealthCare Technologies, Inc. and Genezen Laboratories, Inc. are industry examples of organizations repurposing traditional manufacturing techniques into innovative, scalable solutions that address modern therapeutic demands. Alongside these, established names like Kaneka Eurogentec S.A., Lonza Group Ltd., and MaxCyte, Inc. provide comprehensive insights into the art of effective vector management and production strategy.

The influence of multinational giants like Merck KGaA, Miltenyi Biotec GmbH, Novartis AG, and Oxford Biomedica PLC further underscores the international drive towards excellence in viral vector production. Their contributions extend beyond traditional manufacturing to encompass advanced research, leading-edge technology integration, and holistic quality assurance processes. Likewise, pharmaceutical heavyweights such as Sanofi SA and Sirion-Biotech GmbH inject deep knowledge of market demands and clinical efficacies into production pipelines. In parallel, Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd., Takara Bio Inc., and Thermo Fisher Scientific Inc. have consistently navigated the intricate balance between innovation and regulatory compliance. Companies such as uniQure N.V., VGXI, Inc. by GeneOne Life Science, Waisman Biomanufacturing, and Wuxi AppTec Co., Ltd. round out the spectrum of industry leaders that collectively drive progress, research, and market penetration in the viral vector manufacturing sphere.

The report delves into recent significant developments in the Viral Vector Manufacturing Market, highlighting leading vendors and their innovative profiles. These include ABL Inc., Batavia Biosciences B.V. by CJ Cheiljedang, Biovian Oy, Charles River Laboratories International, Inc., Creative Biogene, Danaher Corporation, FinVector Oy, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., GE HealthCare Technologies, Inc., Genezen Laboratories, Inc., Kaneka Eurogentec S.A., Lonza Group Ltd., MaxCyte, Inc., Merck KGaA, Miltenyi Biotec GmbH, Novartis AG, Oxford Biomedica PLC, Sanofi SA, Sirion-Biotech GmbH, Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd., Takara Bio Inc., Thermo Fisher Scientific Inc., uniQure N.V., VGXI, Inc. by GeneOne Life Science, Waisman Biomanufacturing, and Wuxi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

Successful adaptation in the fast-paced viral vector manufacturing environment hinges on a combination of strategic investments in technology, operational optimization, and proactive market engagement. It is essential that industry leaders continuously monitor emerging trends and invest in research and development initiatives that not only streamline production processes but also enhance product quality and compliance with evolving regulatory standards.

To maintain a competitive edge, companies should consider investing in digital transformation strategies that integrate advanced data analytics with traditional production workflows. This proactive approach will help streamline process optimization, reduce operational costs, and enhance overall product consistency. Simultaneously, fostering strategic partnerships with academic institutions and technology providers can catalyze innovation and facilitate access to breakthrough methodologies.

It is also advisable to focus on modular manufacturing platforms that are designed to be flexible and responsive to market fluctuations. This operational agility supports quick scaling in response to increased demand and ensures that production pipelines remain robust in the face of supply chain disruptions. Additionally, prioritizing innovations in both purification techniques and transfection methods through targeted capital expenditure will further improve yield and efficiency across both upstream and downstream processes.

Stakeholders should also evaluate the evolving regulatory landscape and invest in compliance frameworks that integrate seamlessly with existing quality systems. By emphasizing validation and real-time monitoring protocols, companies can reduce the risk of production delays and ensure that products adhere to the highest safety and efficacy standards. Ultimately, a forward-thinking and agile approach to process innovation, coupled with a focus on strategic regional and technological investments, will position industry leaders at the forefront of tomorrow's therapeutic breakthroughs.

Conclusion

In summary, the viral vector manufacturing landscape is characterized by rapid transformation, underpinned by a convergence of technological innovation, strategic segmentation, and extensive regional diversification. The comprehensive segmentation insights discussed reveal how differences in vector types, workflows, delivery methods, technological applications, disease indications, and end user profiles collectively contribute to a multi-dimensional market dynamic. This layered understanding equips stakeholders with a granular perspective on both the opportunities and challenges prevalent in the sector.

The regional analysis further emphasizes how market nuances differ across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region contributing uniquely to the overall growth trajectory. When combined with insights into the key companies driving market advancements, the holistic picture points to a future where flexibility, innovation, and precision in viral vector production will continue to shape the success of therapeutic solutions.

The evolving trends not only indicate improved operational efficiencies and robust manufacturing protocols but also highlight the importance of agile and forward-thinking strategies in navigating this competitive arena. Ultimately, the landscape is primed for sustained growth, and this concluding overview underscores the imperative for strategic investments and agile methodologies to secure leadership in an increasingly dynamic market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of viral vectors in vaccine production against infectious diseases
      • 5.1.1.2. Growing emphasis on personalized medicine and gene therapy
      • 5.1.1.3. Supportive government initiatives bolstering viral vector manufacturing capabilities globally
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs and inconsistencies in raw materials
    • 5.1.3. Opportunities
      • 5.1.3.1. Enhancement of gene therapy solutions for structural and functional retinal diseases
      • 5.1.3.2. Investment in scalable manufacturing processes for high-volume production of viral vectors
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscapes ensuring compliance with varying standards worldwide
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Vector Type: Rising utilization of adenoviral vector in vaccines and gene therapy owing to strong immunogenic profile and ability to infect non-dividing cells
    • 5.2.2. Application: Rising demand for gene therapy for treating inherited disorders and oncological disorders
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Viral Vector Manufacturing Market, by Vector Type

  • 6.1. Introduction
  • 6.2. Adenoviral Vectors
  • 6.3. Baculoviral Vectors
  • 6.4. Herpes Simplex Vectors
  • 6.5. Lentiviral Vectors
  • 6.6. Plasmid DNA
  • 6.7. Retrovirus

7. Viral Vector Manufacturing Market, by Workflow

  • 7.1. Introduction
  • 7.2. Downstream Processing
    • 7.2.1. Formulation
    • 7.2.2. Purification
  • 7.3. Upstream Processing
    • 7.3.1. Bioreactors
    • 7.3.2. Cell Culture Systems
    • 7.3.3. Media Formulations

8. Viral Vector Manufacturing Market, by Delivery Method

  • 8.1. Introduction
  • 8.2. Ex Vivo
    • 8.2.1. Cell Re-infusion
    • 8.2.2. Cell Transduction
  • 8.3. In Vivo
    • 8.3.1. Direct Injection
    • 8.3.2. Intravenous Route
    • 8.3.3. Oral Administration

9. Viral Vector Manufacturing Market, by Technology

  • 9.1. Introduction
  • 9.2. Purification Techniques
    • 9.2.1. Chromatography
    • 9.2.2. Ultrafiltration
  • 9.3. Transfection Methods
    • 9.3.1. Chemical-Based
    • 9.3.2. Electroporation

10. Viral Vector Manufacturing Market, by Disease Indication

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Genetic Disorders
  • 10.4. Infectious Diseases
  • 10.5. Metabolic Disorders

11. Viral Vector Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. Gene Therapy
    • 11.2.1. Inherited Disorders
    • 11.2.2. Oncological Disorders
    • 11.2.3. Single Gene Mutations
  • 11.3. Oncology Research
    • 11.3.1. Gene Inactivation
    • 11.3.2. Oncolytic Virotherapy
    • 11.3.3. Tumor Suppressor Genes
  • 11.4. Vaccinology
    • 11.4.1. Cancer Vaccines
    • 11.4.2. Infectious Diseases
    • 11.4.3. Zoonotic Diseases

12. Viral Vector Manufacturing Market, by End User

  • 12.1. Introduction
  • 12.2. Biotechnology Companies
    • 12.2.1. Large Enterprises
    • 12.2.2. Start-Ups
  • 12.3. Pharmaceutical Companies
    • 12.3.1. Manufacturing
    • 12.3.2. Research and Development
  • 12.4. Research Institutions
    • 12.4.1. Academic Laboratories
    • 12.4.2. Government Labs

13. Americas Viral Vector Manufacturing Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Viral Vector Manufacturing Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Viral Vector Manufacturing Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Abselion secures GBP 1.1 Million to develop next-gen cell platform for viral vector production
    • 16.3.2. Charles River Laboratories launches innovative viral vector tech transfer program to optimize gene therapy development
    • 16.3.3. Andelyn Biosciences partners with FNIH to accelerate gene therapy for rare diseases through innovative AAV manufacturing
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ABL Inc.
  • 2. Batavia Biosciences B.V. by CJ Cheiljedang
  • 3. Biovian Oy
  • 4. Charles River Laboratories International, Inc.
  • 5. Creative Biogene
  • 6. Danaher Corporation
  • 7. FinVector Oy
  • 8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 9. GE HealthCare Technologies, Inc.
  • 10. Genezen Laboratories, Inc.
  • 11. Kaneka Eurogentec S.A.
  • 12. Lonza Group Ltd.
  • 13. MaxCyte, Inc.
  • 14. Merck KGaA
  • 15. Miltenyi Biotec GmbH
  • 16. Novartis AG
  • 17. Oxford Biomedica PLC
  • 18. Sanofi SA
  • 19. Sirion-Biotech GmbH
  • 20. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • 21. Takara Bio Inc.
  • 22. Thermo Fisher Scientific Inc.
  • 23. uniQure N.V.
  • 24. VGXI, Inc. by GeneOne Life Science
  • 25. Waisman Biomanufacturing
  • 26. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. VIRAL VECTOR MANUFACTURING MARKET MULTI-CURRENCY
  • FIGURE 2. VIRAL VECTOR MANUFACTURING MARKET MULTI-LANGUAGE
  • FIGURE 3. VIRAL VECTOR MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 4. VIRAL VECTOR MANUFACTURING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. VIRAL VECTOR MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. VIRAL VECTOR MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VIRAL VECTOR MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VIRAL VECTOR MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY START-UPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 84. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 86. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 87. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 91. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 94. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 95. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 96. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 97. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 99. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 100. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 101. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 103. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 104. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 106. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 107. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 111. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 114. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 115. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 116. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 118. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 119. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 120. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 121. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 122. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 123. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 125. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 126. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 130. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 133. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 134. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 135. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 137. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 138. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 139. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 141. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 142. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 144. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 145. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 149. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 152. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 153. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 154. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 156. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 157. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 158. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 159. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 160. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 161. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 163. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 164. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 168. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 171. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 172. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 173. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 176. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 216. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 218. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 219. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 220. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 222. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 223. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 227. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 230. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 231. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 234. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 235. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 236. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 237. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 238. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 239. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 241. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 242. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 245. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 246. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 249. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 250. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 251. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 253. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 254. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 255. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 256. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 257. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 258. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 260. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 261. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 265. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 268. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 269. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 270. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 272. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 273. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 274. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 275. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 276. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 277. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 279. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 280. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 284. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 287. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 288. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 289. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 291. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 292. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 293. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 294. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 295. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 296. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 298. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 299. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 300. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 302. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 303. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 305. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 306. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 307. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 308. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 310. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 311. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 312. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 313. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 314. MALAYSIA VIRAL VECTOR MANUFACTUR